Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:JAZZ NASDAQ:MRTX NASDAQ:MRVI NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$6.43-2.9%$5.44$3.96▼$9.85$2.38B0.412.58 million shs1.54 million shsJAZZJazz Pharmaceuticals$110.27-2.0%$108.32$95.49▼$148.06$6.67B0.32831,492 shs404,731 shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/AMRVIMaravai LifeSciences$2.73-5.5%$2.28$1.67▼$10.03$695.22M0.282.29 million shs1.19 million shsUTHRUnited Therapeutics$295.52-1.5%$301.04$266.98▼$417.82$13.33B0.53444,703 shs300,699 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos-3.24%-7.47%+20.75%+48.67%-12.22%JAZZJazz Pharmaceuticals-1.96%+0.75%-0.21%+9.72%+7.86%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%MRVIMaravai LifeSciences-5.54%-1.41%+19.74%+49.18%-64.64%UTHRUnited Therapeutics-1.55%+0.32%+6.89%+5.11%-10.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHCBausch Health Cos3.8414 of 5 stars1.94.00.04.02.33.30.6JAZZJazz Pharmaceuticals4.834 of 5 stars4.51.00.04.01.43.32.5MRTXMirati Therapeutics0.4434 of 5 stars0.00.00.04.70.60.00.6MRVIMaravai LifeSciences3.6225 of 5 stars3.11.00.04.42.60.80.6UTHRUnited Therapeutics4.9895 of 5 stars4.35.00.04.63.53.32.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 1.83Reduce$7.3013.53% UpsideJAZZJazz Pharmaceuticals 2.92Moderate Buy$184.0066.86% UpsideMRTXMirati Therapeutics 0.00N/AN/AN/AMRVIMaravai LifeSciences 2.25Hold$6.64143.18% UpsideUTHRUnited Therapeutics 2.69Moderate Buy$383.0829.63% UpsideCurrent Analyst Ratings BreakdownLatest UTHR, JAZZ, MRVI, BHC, and MRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025UTHRUnited TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$348.00 ➝ $328.007/8/2025UTHRUnited TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$350.00 ➝ $330.006/30/2025UTHRUnited TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$410.00 ➝ $385.006/11/2025JAZZJazz PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$202.006/11/2025UTHRUnited TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$321.00 ➝ $315.006/3/2025JAZZJazz PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$202.006/2/2025UTHRUnited TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$405.005/13/2025MRVIMaravai LifeSciencesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.005/13/2025MRVIMaravai LifeSciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.005/7/2025JAZZJazz PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$182.00 ➝ $172.005/7/2025JAZZJazz PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$167.00 ➝ $155.00(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$9.63B0.25$7.75 per share0.83($0.89) per share-7.22JAZZJazz Pharmaceuticals$4.07B1.64$30.38 per share3.63$67.72 per share1.63MRTXMirati Therapeutics$12.44M331.01N/AN/A$17.31 per share3.39MRVIMaravai LifeSciences$259.18M2.68$0.62 per share4.42$2.28 per share1.20UTHRUnited Therapeutics$2.88B4.63$28.39 per share10.41$144.34 per share2.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos-$46M-$0.11N/A1.38N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)JAZZJazz Pharmaceuticals$560.12M$7.5014.705.894.7611.86%26.62%9.14%7/30/2025 (Estimated)MRTXMirati Therapeutics-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/AMRVIMaravai LifeSciences-$144.85M-$1.14N/AN/AN/A-67.14%-12.91%-6.87%8/6/2025 (Estimated)UTHRUnited Therapeutics$1.20B$25.0611.7910.756.4640.44%19.33%16.73%7/30/2025 (Estimated)Latest UTHR, JAZZ, MRVI, BHC, and MRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025MRVIMaravai LifeSciences-$0.06N/AN/AN/A$47.46 millionN/A7/30/2025Q2 2025BHCBausch Health Cos$0.9320N/AN/AN/A$2.47 billionN/A7/30/2025Q2 2025JAZZJazz Pharmaceuticals-$5.61N/AN/AN/A$1.05 billionN/A7/30/2025Q2 2025UTHRUnited Therapeutics$6.89N/AN/AN/A$802.13 millionN/A5/12/2025Q1 2025MRVIMaravai LifeSciences-$0.07-$0.08-$0.01-$0.21$44.01 million$46.85 million5/6/2025Q1 2025JAZZJazz Pharmaceuticals$4.65$1.68-$2.97-$1.52$984.16 million$897.84 million4/30/2025Q1 2025UTHRUnited Therapeutics$6.29$6.63+$0.34$6.63$726.82 million$794.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/AJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/AMRTXMirati TherapeuticsN/AN/AN/AN/AN/AMRVIMaravai LifeSciencesN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health CosN/A1.350.97JAZZJazz Pharmaceuticals1.283.382.97MRTXMirati TherapeuticsN/A7.547.40MRVIMaravai LifeSciences0.605.965.17UTHRUnited TherapeuticsN/A5.465.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%JAZZJazz Pharmaceuticals89.14%MRTXMirati TherapeuticsN/AMRVIMaravai LifeSciences50.25%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Cos8.05%JAZZJazz Pharmaceuticals4.30%MRTXMirati Therapeutics3.26%MRVIMaravai LifeSciences2.11%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,700370.08 million340.29 millionOptionableJAZZJazz Pharmaceuticals2,80060.51 million57.91 millionOptionableMRTXMirati Therapeutics58770.15 million67.86 millionOptionableMRVIMaravai LifeSciences610254.66 million249.29 millionOptionableUTHRUnited Therapeutics1,30545.11 million40.46 millionOptionableUTHR, JAZZ, MRVI, BHC, and MRTX HeadlinesRecent News About These CompaniesNisa Investment Advisors LLC Sells 4,544 Shares of United Therapeutics Corporation (NASDAQ:UTHR)July 12 at 5:08 AM | marketbeat.comUnited Therapeutics’ DeciPHer-ILD Study: A New Frontier in Pulmonary Hypertension ResearchJuly 11 at 12:07 PM | tipranks.comWhy United Therapeutics (UTHR) is a Top Growth Stock for the Long-TermJuly 11 at 10:46 AM | zacks.comWeil Company Inc. Buys 3,298 Shares of United Therapeutics Corporation (NASDAQ:UTHR)July 11 at 7:12 AM | marketbeat.com1,822 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Acquired by Rehmann Capital Advisory GroupJuly 11 at 5:30 AM | marketbeat.comUBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR)July 10 at 12:56 AM | insidermonkey.comJ.P. Morgan Sticks to Their Buy Rating for United Therapeutics (UTHR)July 10 at 3:50 PM | theglobeandmail.comMorgan Stanley Has Lowered Expectations for United Therapeutics (NASDAQ:UTHR) Stock PriceJuly 10 at 12:44 PM | marketbeat.comUnited Therapeutics’ Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis: Key Insights for InvestorsJuly 9 at 12:16 PM | tipranks.comUnited Therapeutics Corporation (NASDAQ:UTHR) Shares Bought by TD Private Client Wealth LLCJuly 9 at 5:34 AM | marketbeat.comWorld Investment Advisors Has $718,000 Stake in United Therapeutics Corporation (NASDAQ:UTHR)July 9 at 5:04 AM | marketbeat.comTeacher Retirement System of Texas Sells 1,343 Shares of United Therapeutics Corporation (NASDAQ:UTHR)July 9 at 4:12 AM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Price Target Cut to $330.00 by Analysts at JPMorgan Chase & Co.July 8, 2025 | marketbeat.comBrookstone Capital Management Makes New $1.48 Million Investment in United Therapeutics Corporation (NASDAQ:UTHR)July 7, 2025 | marketbeat.comWill United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?July 4, 2025 | zacks.comNew York State Teachers Retirement System Lowers Holdings in United Therapeutics Corporation (NASDAQ:UTHR)July 3, 2025 | marketbeat.comUnited Therapeutics Corporation (NASDAQ:UTHR) Holdings Raised by Sumitomo Mitsui Trust Group Inc.July 3, 2025 | marketbeat.comWhy Investors Need to Take Advantage of These 2 Medical Stocks NowJuly 2, 2025 | zacks.comAmalgamated Bank Trims Position in United Therapeutics Corporation (NASDAQ:UTHR)July 2, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Decreases Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)July 2, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Sells 2,214 Shares of United Therapeutics Corporation (NASDAQ:UTHR)July 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUTHR, JAZZ, MRVI, BHC, and MRTX Company DescriptionsBausch Health Cos NYSE:BHC$6.43 -0.19 (-2.87%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$6.42 -0.01 (-0.23%) As of 07/11/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Jazz Pharmaceuticals NASDAQ:JAZZ$110.27 -2.21 (-1.96%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$110.37 +0.10 (+0.09%) As of 07/11/2025 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Mirati Therapeutics NASDAQ:MRTXMirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.Maravai LifeSciences NASDAQ:MRVI$2.73 -0.16 (-5.54%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.74 +0.00 (+0.18%) As of 07/11/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.United Therapeutics NASDAQ:UTHR$295.52 -4.64 (-1.55%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$294.36 -1.15 (-0.39%) As of 07/11/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
